[go: up one dir, main page]

PE20050924A1 - Compuestos de tiazolidinonas como inhibidores de quinasa tipo polo (plk) - Google Patents

Compuestos de tiazolidinonas como inhibidores de quinasa tipo polo (plk)

Info

Publication number
PE20050924A1
PE20050924A1 PE2004001044A PE2004001044A PE20050924A1 PE 20050924 A1 PE20050924 A1 PE 20050924A1 PE 2004001044 A PE2004001044 A PE 2004001044A PE 2004001044 A PE2004001044 A PE 2004001044A PE 20050924 A1 PE20050924 A1 PE 20050924A1
Authority
PE
Peru
Prior art keywords
alkyl
ethyl
plk
polo
iliden
Prior art date
Application number
PE2004001044A
Other languages
English (en)
Inventor
Gerhard Siemeister
Hans Briem
Volker Schulze
Lars Wortmann
Herbert Schneider
Holger Hess-Stumpp
Uwe Eberspacher
Wolfgang Schwede
Knut Eis
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20050924A1 publication Critical patent/PE20050924A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE Q ES ARILO O HETEROARILO; A Y B SON CADA UNO H, HALOGENO, HIDROXI, AMINO, ALQUILO C1-C3, ENTRE OTROS; X ES -NH-, -NR5-; R1 ES ALQUILO C1-C4, ALILO O PROPARGILO OPCIONALMENTE SUSTITUIDOS; ENTRE OTROS; R2 ES H, ALQUILO C1-C6, ALCOXI C1-C6, ALQUENILO C1-C6, ENTRE OTROS; R5 ALQUILO C1-C6, ALQUENILO C3-C6, ALQUINILO C3-C6 OPCIONALMENTE SUSTITUIDO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ESTER ETILICO DEL ACIDO (E O Z)-CIANO-(3-ETIL-5-(E/Z)-{[4-(2-MORFOLIN-4-IL-ETANSULFONILAMINO)-FENILAMINO]-METILEN}-4-OXO-TIAZOLIDIN-2-ILIDEN)-ACETICO; ESTER ALILICO DEL ACIDO (E O Z)-CIANO-(3-ETIL-5-(E/Z)-({4-[3-(4-METIL-PIPERAZIN-1-IL)-PROPIONILAMINO]-FENILAMINO}-METILEN}-4-OXO-TIAZOLIDIN-2-ILIDEN)-ACETICO; ESTER ETILICO DEL ACIDO (E O Z)-CIANO-[3-ETIL-4-OXO-5-(E/Z)-(M-TOLILAMINO-METILEN)-TIAZOLIDIN-2-ILIDEN]-ACETICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN METODO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA TIPO POLO (PLK) UTILES EN EL TRATAMIENTO DE CANCER, ENFERMEDADES AUTOINMUNES, CARDIOVASCULARES, INFECCIOSAS, ENTRE OTRAS
PE2004001044A 2003-10-31 2004-10-29 Compuestos de tiazolidinonas como inhibidores de quinasa tipo polo (plk) PE20050924A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10351744A DE10351744A1 (de) 2003-10-31 2003-10-31 Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PE20050924A1 true PE20050924A1 (es) 2005-11-25

Family

ID=34530142

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001044A PE20050924A1 (es) 2003-10-31 2004-10-29 Compuestos de tiazolidinonas como inhibidores de quinasa tipo polo (plk)

Country Status (20)

Country Link
US (1) US20070037862A1 (es)
EP (1) EP1678153A1 (es)
JP (1) JP2007509892A (es)
KR (1) KR20060098374A (es)
CN (1) CN1902185A (es)
AR (1) AR046347A1 (es)
AU (1) AU2004285682A1 (es)
BR (1) BRPI0416005A (es)
CA (1) CA2544267A1 (es)
CR (1) CR8385A (es)
DE (1) DE10351744A1 (es)
EA (1) EA200600833A1 (es)
EC (1) ECSP066588A (es)
IL (1) IL175245A0 (es)
NO (1) NO20062453L (es)
PE (1) PE20050924A1 (es)
RS (1) RS20060294A (es)
TW (1) TW200530230A (es)
WO (1) WO2005042505A1 (es)
ZA (1) ZA200604432B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519590A (ja) 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
DE102004061503A1 (de) * 2004-12-15 2006-06-29 Schering Ag Metasubstituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
JP2008524139A (ja) * 2004-12-15 2008-07-10 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト メタ置換チアゾリノン類、それらの製造及び医薬としての使用
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
DE102005055892A1 (de) * 2005-11-22 2007-05-24 Henkel Kgaa Neue Kupplerkomponenten
WO2007089862A2 (en) * 2006-01-31 2007-08-09 Elan Pharmaceuticals, Inc. Alpha-synuclein kinase
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
FR2904317A1 (fr) * 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
EP2085390A1 (en) * 2008-01-31 2009-08-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
CA2713753A1 (en) * 2008-02-13 2009-08-20 Elan Pharma International Limited Alpha-synuclein kinase
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2141163A1 (de) * 2008-07-02 2010-01-06 Bayer Schering Pharma AG Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
WO2010121675A2 (en) 2008-12-18 2010-10-28 F. Hoffmann-La Roche Ag Thiazolyl-benzimidazoles
CN102584809B (zh) * 2011-01-14 2014-12-24 湘北威尔曼制药股份有限公司 胺基噻唑烷酮化合物及其制备方法与在制备抗肿瘤药物中的应用
WO2014069434A1 (ja) * 2012-10-30 2014-05-08 カルナバイオサイエンス株式会社 新規チアゾリジノン誘導体
CN110461330A (zh) * 2017-01-18 2019-11-15 科赫罗斯生物科学股份有限公司 用于治疗亨廷顿氏病的PPARγ激动剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153875B2 (en) * 2001-03-07 2006-12-26 Incyte San Diego Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
HRP20041142A2 (en) * 2002-05-03 2005-10-31 Schering Aktiengesellschaft Thiazolidinones and the use thereof as polo-like kinase inhibitors

Also Published As

Publication number Publication date
CA2544267A1 (en) 2005-05-12
US20070037862A1 (en) 2007-02-15
BRPI0416005A (pt) 2007-01-02
KR20060098374A (ko) 2006-09-18
ECSP066588A (es) 2006-10-17
WO2005042505A1 (de) 2005-05-12
ZA200604432B (en) 2009-09-30
JP2007509892A (ja) 2007-04-19
CR8385A (es) 2006-10-04
EP1678153A1 (de) 2006-07-12
TW200530230A (en) 2005-09-16
NO20062453L (no) 2006-07-28
CN1902185A (zh) 2007-01-24
EA200600833A1 (ru) 2007-02-27
AR046347A1 (es) 2005-12-07
AU2004285682A1 (en) 2005-05-12
RS20060294A (sr) 2008-08-07
DE10351744A1 (de) 2005-06-16
IL175245A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
PE20050924A1 (es) Compuestos de tiazolidinonas como inhibidores de quinasa tipo polo (plk)
PE20060215A1 (es) 4-fenilamino-quinazolin-6-il-amidas
PE20081059A1 (es) Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk)
AR078944A1 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
PE20110598A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20090952A1 (es) Compuestos de pirazol moduladores de raf
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20040155A1 (es) Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20090813A1 (es) Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk
PE20050872A1 (es) Compuestos 5-fenil-tiazol-2-il-amida como inhibidores de la enzima fosfatidilinositol 3-cinasa
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
PE20120305A1 (es) Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20080856A1 (es) Inhibidores de metaloproteasas de matriz
TW200635585A (en) Monocyclic substituted methanones
CO5700757A2 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed